-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Kyverna Therapeutics, Lowers Price Target to $4

Benzinga·04/03/2025 11:28:54
Listen to the news
HC Wainwright & Co. analyst Mitchell Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and lowers the price target from $6 to $4.